These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Theranostics of Metastatic Prostate Cancer Applying Mirzaei S; Mohammed F; Zandieh S Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357 [TBL] [Abstract][Full Text] [Related]
10. Third-line treatment and von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284 [TBL] [Abstract][Full Text] [Related]
11. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
12. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
13. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
15. Early Prostate-Specific Antigen Changes and Clinical Outcome After Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687 [TBL] [Abstract][Full Text] [Related]
16. Cao J; Chen Y; Hu M; Zhang W Ann Nucl Med; 2021 Aug; 35(8):861-870. PubMed ID: 34176105 [TBL] [Abstract][Full Text] [Related]
17. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387 [TBL] [Abstract][Full Text] [Related]
18. Radioligand Therapy With Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089 [No Abstract] [Full Text] [Related]
19. Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224 [TBL] [Abstract][Full Text] [Related]
20. Response Assessment and Prediction of Progression-Free Survival by Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]